Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam

MUNICH, Oct. 13, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health, a clinical-stage precision psychiatry biopharmaceutical company developing personalized treatments powered by predictive companion diagnostics, today announced it presented a retrospective analysis demonstrating distinct bimodal response distributions in patients treated with nelivaptan (BH-200) at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in Amsterdam.

The Company’s poster, titled “Precision Psychiatry in MDD: Finite Mixture Modeling of Nelivaptan Response Suggests Distinct Responder Classes,” presents new findings that support the biological and methodological rationale for HMNC’s ongoing Phase 2b OLIVE trial. That trial integrates a genetic companion diagnostic to identify patients most likely to benefit from vasopressin V1b receptor inhibition.

The analysis visualizes a bimodal distribution in improvement of depressive symptoms observed in Sanofi’s earlier Phase 2 study in Major Depressive Disorder (NCT00358631). Patients treated with nelivaptan exhibited two distinct clusters of response: one subgroup showed a mean change of –17.1 points on the 17-item Hamilton Depression Rating Scale (HAM-D17), while another showed –3.9 points compared with a –7.1-point change in the placebo group after eight weeks of treatment.

These findings suggest that a biologically defined subset of individuals with Major Depressive Disorder (MDD) may derive substantial benefit from vasopressin V1b receptor antagonism. This is consistent with HMNC’s hypothesis that hypothalamic-pituitary-adrenal (HPA) axis dysregulation, also referred to as stress-axis dysfunction, plays a key role in treatment-resistant forms of depression.

Perturbation of the HPA axis has been implicated in approximately 30–50% of patients with MDD. By selectively inhibiting vasopressin V1b receptor signaling, nelivaptan targets this disturbed stress response system. HMNC’s OLIVE trial co-develops BH-200 with a proprietary genetic companion diagnostic, aiming to prospectively identify and treat this biologically defined subgroup.

“The Sanofi dataset provided a rare opportunity to observe a clear bimodal response pattern, where one group of patients experienced a much greater improvement on nelivaptan,” said Hans Eriksson, MD, PhD, MBA, Chief Medical Officer of HMNC Brain Health. “That separation reinforces our rationale for pairing BH-200 with a genetic companion diagnostic in the OLIVE study. While the earlier trial could not incorporate biomarker data, our work now builds directly on those findings, helping us move from observation to prediction in how we treat depression.”

About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a precision psychiatry biopharmaceutical company developing personalized treatments for depression based on predictive genetic selection tools. The company’s pipeline includes three Phase 2 programs in Major Depressive Disorder (MDD): Nelivabon, developing a vasopressin V1b receptor antagonist paired with a proprietary genetic selection tool; Cortibon, developing a CRHR1 antagonist with a matching companion diagnostic; and Ketabon, developing KET01, a prolonged-release oral ketamine formulation designed for safe, at-home treatment.

Media contacts:
Anne Donohoe
+1 732-620-0033
hmnc@kcsa.com

Investors:
Maximilian Doebler
Chief Business Officer
HMNC Brain Health
maximilian.doebler@hmnc-brainhealth.com


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.